The role of inflammatory theory in the pathogenesis of atrial fibrillation

Давтян, К. В.; Калемберг, А. А.; Царева, Е. Н.; Благова, О В; Харлап, М. С.

doi:10.15829/1560-4071-2019-7-110-114

Cited by 5 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В контексте применения противоопухолевых ЛС, следует отметить, что в инициации, поддержании и прогрессировании ФП хорошо изучена роль воспаления [249]: повышение уровня ряда медиаторов воспаления приводит к электрическому и структурному ремоделированию миокарда, среди них С-реактивный белок, интерлейкин (ИЛ) 6, ИЛ-2, фактор некроза опухоли альфа (ФНО-α) и др. [250,251].…”

Section: патофизиологические механизмыunclassified

Drug-Induced Atrial Fibrillation / Atrial Flutter

Остроумова

Chernyaeva

Кочетков

et al. 2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Drug-induced atrial fibrillation / flutter (DIAF) is a serious and potentially life-threatening complication of pharmacotherapy. Purpose of the work: systematization and analysis of scientific literature data on drugs, the use of which can cause the development of DIAF, as well as on epidemiology, pathophysiological mechanisms, risk factors, clinical picture, diagnosis and differential diagnosis, treatment and prevention of DIAF. Analysis of the literature has shown that many groups of drugs can cause the development of DIAF, with a greater frequency while taking anticancer drugs, drugs for the treatment of the cardiovascular, bronchopulmonary and central nervous systems. The mechanisms and main risk factors for the development of DIAF have not been finally established and are known only for certain drugs, therefore, this section requires further study. The main symptoms of DIAF are due to the severity of tachycardia and their influence on the parameters of central hemodynamics. For diagnosis, it is necessary to conduct an electrocardiogram (ECG) and Holter monitoring of an ECG and echocardiography. Differential diagnosis should be made with AF, which may be caused by other causes, as well as other rhythm and conduction disturbances. Successful treatment of DIAF is based on the principle of rapid recognition and immediate discontinuation of drugs (if possible), the use of which potentially caused the development of adverse drug reactions (ADR). The choice of management strategy: heart rate control or rhythm control, as well as the method of achievement (medication or non-medication), depends on the specific clinical situation. For the prevention of DIAF, it is necessary to instruct patients about possible symptoms and recommend self-monitoring of the pulse. It is important for practitioners to be wary of the risk of DIAF due to the variety of drugs that can potentially cause this ADR.

show abstract

Section: патофизиологические механизмыunclassified

Drug-Induced Atrial Fibrillation / Atrial Flutter

Остроумова

Chernyaeva

Кочетков

et al. 2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

“…К таким медиаторам относятся С-реактивный белок (СРБ), интерлейкин-6 (ИЛ-6), ИЛ-2, фактор некроза опухоли-альфа (ФНО-α) и др. [29,30,31]. Системное воспаление, непосредственно связанное с онкологическим заболеванием и опосредованное ФНО-α, ядерным фактором-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, NF-κB) и фактором торможения миграции макрофагов (macrophage migration inhibitory factor, MIF), может приводить к структурному ремоделированию предсердий [32].…”

Section: патофизиологические механизмы развития фибрилляции предсердий ассоциированной с применением противоопухолевых лекарственных средunclassified

Atrial Fibrillation Associated with Anticancer Drugs

Остроумова

Chernyaeva

Кочетков

et al. 2020

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

Atrial fibrillation is a serious adverse reaction associated with the use of anticancer drugs. The aim of the study was to analyse scientific literature on the prevalence, pathophysiological mechanisms, and risk factors of anticancer drug-induced atrial fibrillation, ways of its prevention and treatment. The results of the study showed that the incidence of drug-induced atrial fibrillation varies depending on a specific anticancer drug and ranges from 1 to 86%. It is associated with the use of herbal anticancer agents, alkylating agents, protein kinase inhibitors, monoclonal antibodies, immunosuppressants, antitumor antibiotics, antimetabolites, hormonal anticancer agents, hormone antagonists, etc. Most often, atrial fibrillation develops following the use of such drugs as gemcitabine (in combination with vinorelbine), cisplatin, melphalan, ibrutinib, cetuximab, trastuzumab, alemtuzumab, and doxorubicin. It was demonstrated that the pathophysiological mechanisms underlying the development of atrial fibrillation induced by anticancer drugs include electrophysiological abnormalities, myocardial injury, inflammation, immune response, apoptosis, and oxidative stress. Risk factors for the development of anticancer drug-induced atrial fibrillation are not clearly defined yet and continue to be the subject of research. Prevention of drug-induced atrial fibrillation in cancer patients requires a multidisciplinary approach involving participation of an oncohematologist and a cardiologist. The doctors in charge should also be vigilant regarding potential development of this adverse reaction.

show abstract

“…The absence of an obvious cause of idiopathic AF can complicate the choice of medical and surgical treatment tactics, reduce the effectiveness Галектин-3 и изменения миокарда при ФП Galectin-3 and myocardial changes in AF 2023, Vol. 25,4 2023, Т. 25, № 4 of radiofrequency ablation, and have unpredictable effects on drug therapy [3].…”

Section: Introductionmentioning

confidence: 99%

“…An analysis of literature data over the past decade has shown the widespread use of laboratory biomarkers, reflecting various aspects and pathogenetic mechanisms of the development and progression of AF [4,8]. Recently the role and prognostic value of the biomarker galectin-3 (Gal-3) has been actively studied in AF.…”

Section: Introductionmentioning

confidence: 99%

Laboratory biomarker galectin-3 in the diagnostics of myocardial inflammatory changes in patients with atrial fibrillation

2023

View full text Add to dashboard Cite

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias. Numerous data indicate a significant contribution of myocardial inflammatory changes in the development and progression of AF. The search for new laboratory biomarkers to assess the activity of myocardial inflammatory processes, and the study of their diagnostic significance for noninvasive diagnosis in patients with AF is relevant. Therefore, the aim was to study the features of the serum level of the biomarker Gal-3 and to identify its relationship with inflammatory changes in the myocardium in patients with AF. Depending on the results of histological studies, the patients were divided into 2 groups: group 1 – with morphologically verified active lymphocytic myocarditis (ALM), group 2 – with lymphocytic infiltration (LI). Analysis of the frequency of detection and severity of the inflammatory process in the myocardium showed that activity of 4-5 scores was detected only in group 1. In 2nd group, activity of the inflammatory process in most patients was 1 score. All patients with LI mild interstitial inflammation were showed. In the ALM group moderate and severe interstitial inflammation was detected. A high number of CD3+ and CD45+ cells were found in 1st group compared to group 2 (p < 0.001).There were no significant intergroup differences in the serum level of Gal-3. At the same time, in 1st group showed a significant decrease in Gal-3 in 6 months after treatment (p = 0.028). Positive correlations of Gal-3 with the severity of the inflammatory process and endocardial involvement were revealed in patients with ALM. The association of serum Gal-3 levels with CD68+ levels in 1st group was detected (R = 0.48, p = 0.030). In 2nd group, a correlation between the level of Gal-3 in 6 months after ablation with infiltration of CD45+ cells was found (R = 0.69, p = 0.003). Thus, in patients with AF and active lymphocytic myocarditis, significant associations were established between biomarkers of Gal-3 and inflammatory changes in the myocardium. This confirms the important role of Gal-3 as a participant in the inflammatory process.

show abstract

The role of inflammatory theory in the pathogenesis of atrial fibrillation

Cited by 5 publications

References 27 publications

Drug-Induced Atrial Fibrillation / Atrial Flutter

Drug-Induced Atrial Fibrillation / Atrial Flutter

Atrial Fibrillation Associated with Anticancer Drugs

Laboratory biomarker galectin-3 in the diagnostics of myocardial inflammatory changes in patients with atrial fibrillation

Contact Info

Product

Resources

About